ArticlePDF Available

Extracorporeal membrane oxygenation in curing a young man after modified Fontan operation: A case report

Authors:

Abstract

BACKGROUND The Fontan operation is the only treatment option to change the anatomy of the heart and help improve patients’ hemodynamics. After successful operation, patients typically recover the ability to engage in general physical activity. As a better ventilatory strategy, extracorporeal membrane oxygenation (ECMO) provides gas exchange via an extracorporeal circuit, and is increasingly being used to improve respiratory and circulatory function. After the modified Fontan operation, circulation is different from that of patients who are not subjected to the procedure. This paper describe a successful case using ECMO in curing influenza A infection in a young man, who was diagnosed with Tausing-Bing syndrome and underwent Fontan operation 13 years ago. The special cardiac structure and circulatory characteristics are explored in this case. CASE SUMMARY We report a successful case using ECMO in curing influenza A infection in a 23-year-old man, who was diagnosed with Tausing-Bing syndrome and underwent Fontan operation 13 years ago. The man was admitted to the intensive care unit with severe acute respiratory distress syndrome as a result of influenza A infection. He was initially treated by veno-venous (VV) ECMO, which was switched to veno-venous-arterial ECMO (VVA ECMO) 5 d later. As circulation and respiratory function gradually improved, the VVA ECMO equipment was removed on May 1, 2018. The patient was successfully withdrawn from artificial ventilation on May 28, 2018 and then discharged from hospital on May 30, 2018. CONCLUSION After the modified Fontan operation, circulation is different compared with that of patients who are not subjected to the procedure. There are certainly many differences between them when they receive the treatment of ECMO. Due to the special cardiac structure and circulatory characteristics, an individualized liquid management strategy is necessary and it might be better for them to choose an active circulation support earlier.
WJCC https://www.wjgnet.com 10614 October 16, 2022 Volume 10 Issue 29
World Journal of
Clinical Cases
W J C C
Submit a Manuscript: https://www.f6publishing.com World J Clin Cases 2022 October 16; 10(29): 10614-10621
DOI: 10.12998/wjcc.v10.i29.10614 ISSN 2307-8960 (online)
CASE REPORT
Extracorporeal membrane oxygenation in curing a young man after
modified Fontan operation: A case report
He-Bing Guo, Jian-Bo Tan, Yong-Chao Cui, Hao-Feng Xiong, Chuan-Sheng Li, Yu-Feng Liu, Yao Sun, Lin Pu,
Pan Xiang, Ming Zhang, Jing-Jing Hao, Ning-Ning Yin, Xiao-Tong Hou, Jing-Yuan Liu
Specialty type: Critical care
medicine
Provenance and peer review:
Unsolicited article; Externally peer
reviewed.
Peer-review model: Single blind
Peer-review report’s scientific
quality classification
Grade A (Excellent): A
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Apiratwarakul K,
Thailand; Cabezuelo AS, Spain;
Sharma D, India
Received: April 14, 2022
Peer-review started: April 14, 2022
First decision: July 11, 2022
Revised: July 14, 2022
Accepted: August 30, 2022
Article in press: August 30, 2022
Published online: October 16, 2022
He-Bing Guo, Jian-Bo Tan, Hao-Feng Xiong, Chuan-Sheng Li, Yu-Feng Liu, Yao Sun, Lin Pu, Pan
Xiang, Ming Zhang, Jing-Jing Hao, Ning-Ning Yin, Jing-Yuan Liu, Department of Critical Care
Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Yong-Chao Cui, Xiao-Tong Hou, Center for Cardiac Intensive Care, Beijing Anzhen Hospital,
Capital Medical University, Beijing 100029, China
Corresponding author: Jing-Yuan Liu, MD, Associate Professor, Doctor, Department of Critical
Care Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street,
Chaoyang District, Beijing 100015, China. dtyyicu@ccmu.edu.cn
Abstract
BACKGROUND
The Fontan operation is the only treatment option to change the anatomy of the
heart and help improve patients’ hemodynamics. After successful operation,
patients typically recover the ability to engage in general physical activity. As a
better ventilatory strategy, extracorporeal membrane oxygenation (ECMO)
provides gas exchange via an extracorporeal circuit, and is increasingly being used
to improve respiratory and circulatory function. After the modified Fontan
operation, circulation is different from that of patients who are not subjected to
the procedure. This paper describe a successful case using ECMO in curing
influenza A infection in a young man, who was diagnosed with Tausing-Bing
syndrome and underwent Fontan operation 13 years ago. The special cardiac
structure and circulatory characteristics are explored in this case.
CASE SUMMARY
We report a successful case using ECMO in curing influenza A infection in a 23-
year-old man, who was diagnosed with Tausing-Bing syndrome and underwent
Fontan operation 13 years ago. The man was admitted to the intensive care unit
with severe acute respiratory distress syndrome as a result of influenza A
infection. He was initially treated by veno-venous (VV) ECMO, which was switch-
ed to veno-venous-arterial ECMO (VVA ECMO) 5 d later. As circulation and
respiratory function gradually improved, the VVA ECMO equipment was
removed on May 1, 2018. The patient was successfully withdrawn from artificial
ventilation on May 28, 2018 and then discharged from hospital on May 30, 2018.
CONCLUSION
Guo HB et al. ECMO in a patient after Fontan operation
WJCC https://www.wjgnet.com 10615 October 16, 2022 Volume 10 Issue 29
After the modified Fontan operation, circulation is different compared with that of patients who
are not subjected to the procedure. There are certainly many differences between them when they
receive the treatment of ECMO. Due to the special cardiac structure and circulatory characteristics,
an individualized liquid management strategy is necessary and it might be better for them to
choose an active circulation support earlier.
Key Words: Acute respiratory distress syndrome; Extracorporeal membrane oxygenation; Modified Fontan
operation; Tausing-Bing syndrome; Case report
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: After the modified Fontan operation, circulation is different from that of patients who are not
subjected to the procedure. In this article, we describe a 23-year-old man, with a history of modified
Fontan operation for Tausing-Bing syndrome, who was admitted to the intensive care unit with severe
acute respiratory distress syndrome as a result of influenza A infection. The man was initially treated by
veno-venous extracorporeal membrane oxygenation (ECMO), which was switched to veno-venous-arterial
ECMO 5 d later. As circulation and respiratory function gradually improved, the veno-venous-arterial
ECMO equipment was successfully removed. Then, the man was discharged from hospital successfully.
This case highlights that an individualized liquid management strategy is necessary and it might be better
for such patients to choose an active circulation support earlier.
Citation: Guo HB, Tan JB, Cui YC, Xiong HF, Li CS, Liu YF, Sun Y, Pu L, Xiang P, Zhang M, Hao JJ, Yin NN,
Hou XT, Liu JY. Extracorporeal membrane oxygenation in curing a young man after modified Fontan operation: A
case report. World J Clin Cases 2022; 10(29): 10614-10621
URL: https://www.wjgnet.com/2307-8960/full/v10/i29/10614.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i29.10614
INTRODUCTION
The Fontan operation is the only treatment option to change the anatomy of the heart and help improve
patients’ hemodynamics[1]. The patient’s circulation after the Fontan surgery is different from that of a
normal patient. The mortality of patients diagnosed with acute respiratory distress syndrome (ARDS)
ranges from 17.3% to 41.4% among critically ill patients with H1N1 infection[2,3], and many patients
need the help of extracorporeal membrane oxygenation (ECMO). Whereas, due to the special circulation
after the Fontan surgery, supporting Fontan patients on ECMO carries high morbidity and mortality[4].
Few articles have described the special circulation about cases who receive ECMO after the modified
Fontan operation. We herein report such a case.
CASE PRESENTATION
Chief complaints
A 23-year-old male patient presented to the general intensive care unit (ICU) of Beijing Ditan Hospital
Affiliated to Capital Medical University on April 5, 2018 mainly due to fever for 5 d, with 39.1 °C as the
highest temperature.
History of present illness
Upon history-taking, the patient revealed that he got a fever with 39.1 °C as the highest temperature on
April 1, 2018. He received treatment at a local health clinic, where he was prescribed with cephalosporin
antibiotics on April 2, 2018. Then, the patient saw a doctor at Beijing Huairou District Hospital. A chest
computed tomography (CT) scan showed large consolidation of the lower lobe of the right lung and
superior lobe of the left lung on April 4, 2018. Arterial blood gas analysis revealed: pH 7.476, PCO2 22
mmHg, PO2 54.1 mmHg, and HCO3- 20.4 mmol/L. The fraction of inspiration O2 (FiO2) at the time of
taking arterial blood samples was 21%. The antigen of influenza A was positive. Then, he was
transferred to the general ICU of Beijing Ditan Hospital Affiliated Capital Medical University for further
treatment on April 5, 2018.
Guo HB et al. ECMO in a patient after Fontan operation
WJCC https://www.wjgnet.com 10616 October 16, 2022 Volume 10 Issue 29
History of past illness
At birth, the patient was diagnosed with atrial septal defect, ventricular septal defect, pulmonary artery
stenosis, and right ventricular double outlet, also known as Tausing-Bing syndrome. He received the
modified Fontan operation 13 years ago when he was 10 years old. In the surgery, the pulmonary orifice
was sutured, and the tricuspid valve was sewn closed, then the left auricle was connected with the
pulmonary artery to ensure stable cardiopulmonary circulation during the operation. He recovered well
and was able to perform general physical activity easily by himself after the operation. Three years ago,
echocardiography at the regular visit revealed a double outlet in the right ventricle. Moreover, it was
also observed that he showed right atrial enlargement and aortic valve regurgitation. The ejection
fraction of the young man was 50%.
Personal and family history
The patient had no previous or family history of similar illnesses.
Physical examination
The physical examination revealed the following: Temperature 38.4 °C, blood pressure 86/54 mmHg,
respiration rate 40 times/min, pulse rate 110 times/min, and SPO2 80%. The breath sounds of both lungs
were thick and moist rales can be easily heard. Arrhythmia and dropped-beat pulse were found in the
physical examination. Due to respiratory failure and septic shock, his skin was wet, cold, and bluish.
Laboratory examinations
Laboratory tests at the time of admission to the ICU were as follows: White blood cell count: 11.89 × 109
/L (reference range, 4-10 × 109/L); neutrophil percentage: 84.94% (reference range, 50%-70%);
hemoglobin: 173.10 g/L (reference range, 110-150 g/L); hematocrit: 48.70% (reference range, 35%-45%);
platelet count: 178.00 × 109/L (reference range, 100-300 × 109/L); sodium: 128.5 mmol/L (reference
range, 137-147 mmol/L); creatinine 279.6 µmol/L (reference range, 41-73 µmol/L); procalcitonin: 4.51
ng/mL (reference range, < 0.05 ng/mL); C-reactive protein: 212.9 mg/L (reference range, 0-5 ng/mL);
alanine aminotransferase 48.6 U/L (reference range, 7-40 U/L); aspartate aminotransferase: 100.4 U/L
(reference range, 13-35 U/L); total bilirubin: 26.2 µmol/L (reference range, 0-18.8 µmol/L); direct
bilirubin: 21.4 µmol/L (reference range, 0-6.8 µmol/L).
Imaging examinations
The chest X-ray of the patient on admission is shown in Figure 1A. The chest X-ray of the patient at the
first day of his receiving the veno-venous (VV) ECMO therapy is shown in Figure 1B.
MULTIDISCIPLINARY EXPERT CONSULTATION
Enhanced chest CT was performed on April 9, 2018 (Figure 2A and B), which revealed postoperative
changes of the heart and bilateral pneumonia changes. A small amount of bilateral pleural effusion was
also detected. The direction of blood flow is shown in Figure 2C. The chest X-ray of the patient at the
second day and ninth day of his receiving the veno-venous-arterial (VVA ECMO) therapy is,
respectively, shown in Figure 2D and E. The chest X-ray before the patient finished the VVA ECMO
therapy is shown in Figure 2F. The chest X-ray and lung CT images on May 24, 2018 are shown in
Figure 2G and H, respectively.
FINAL DIAGNOSIS
The patient was mainly diagnosed with type A influenza. Other diagnoses were pulmonary infection,
severe respiratory failure, acute kidney injury, acute hepatic injury, electrolyte disturbance, and atrial
fibrillation.
TREATMENT
Upon admission into the ICU, the patient’s APACHE II and Sequential Organ Failure Assessment scores
were, respectively, 22 and 10. A Venturi mask was used for supporting respiratory function, and the
oxygen flow volume was 15 L/min. The saturation of pulse oxygen of the patient was 80%. Meanwhile,
he had difficulty in breathing and breathed 40 breaths per minute. The arterial blood gas analysis before
mechanical ventilation indicated the following: pH 7.45, PCO2 30 mmHg, and PO2 48.2 mmHg. Due to
severe ARDS, the young patient was intubated on April 5, 2018, and the ventilator mode was
intermittent positive pressure ventilation. Other parameters were as follows: FiO2 100%, tidal volume
Guo HB et al. ECMO in a patient after Fontan operation
WJCC https://www.wjgnet.com 10617 October 16, 2022 Volume 10 Issue 29
Figure 1 Chest X-rays of the patient at admission and the first day of receiving veno-venous extracorporeal membrane oxygenation
therapy. A: Chest X-ray of the patient at admission to the intensive care unit; B: Chest X-ray of the patient at the first day of receiving veno-venous extracorporeal
membrane oxygenation therapy.
Figure 2 Follow-up images at two months after veno-venous extracorporeal membrane oxygenation therapy. A: Computed tomography (CT)
images of the lung on April 9, 2018; B: Chest enhanced CT images on April 9, 2018; a: The right atrium; b: The left atrium; c: The left ventricle; d: The right ventricle;
e: The thoracic aorta; f: The ascending aorta; g: The aortic arch; h: The pulmonary vein; i: The pulmonary artery; C: Diagram of Fontan circulation; D: Chest X-ray of
the patient at the second day of receiving veno-venous extracorporeal membrane oxygenation (VVA ECMO) therapy; E: Chest X-ray of the patient at the ninth day of
receiving VV-A ECMO therapy; F: Chest X-ray before the patient finished VV-A ECMO therapy; G: Chest X-ray on May 24, 2018; and H: Lung CT images on May 24,
2018.
560 mL, respiratory frequency 20 times/min, positive end-expiratory pressure = 10 cmH2O, and peak
airway pressure 23 cm H2O. Moxifloxacin hydrochloride and paramivir were used to combat infection
when the patient was admitted to the ICU. Anti-infective drugs were switched to cefoperazone-
sulbactam sodium and vancomycin hydrochloride on April 9, 2018. To control a fungal infection,
voriconazole was used on April 9, 2018.
Guo HB et al. ECMO in a patient after Fontan operation
WJCC https://www.wjgnet.com 10618 October 16, 2022 Volume 10 Issue 29
Due to the special heart structure after the modified Fontan operation, the central venous pressure
(CVP) of the young man was 40 mmHg on admission. As a result of septic shock, noradrenaline was
used to raise blood pressure. For severe AKI, hyperkalemia, and metabolic acidosis, continuous renal
replacement therapy was initiated when the patient was admitted to the ICU. Even if the protective lung
ventilation strategy and ventilation in prone position were properly conducted after mechanical
ventilation, his respiratory failure was persistent and did not significantly improve. The arterial blood
gas analysis revealed the following: pH 7.193, PCO2 48 mmHg, PO2 52 mmHg, base excess -10 mmol/L,
and lactate 1.34 mmol/L. VV ECMO was applied to correct the respiratory failure on April 6, 2018. The
two vein indwelling catheters were established, respectively, in the left femoral and right internal
jugular veins. The initial parameters of VV ECMO were as follows: Rotation speed 3100 turns/min,
blood flow volume 4.3 L/min, oxygen flow volume 4.5 L/min, and FiO2 100%.
As an attempt to ameliorate severe heart failure and cardiogenic shock, the VV ECMO procedure was
replaced by VVA ECMO on April 11, 2018. The patient’s right femoral artery was punctured and
intubated as the infusion tube, and combined deep venous catheters inserted in the left femoral vein and
right internal jugular vein were used as the drainage tube. The initial parameters of VVA ECMO were as
follows: Rotation speed 3800 turns/min, blood flow volume 4 L/min, oxygen flow volume 4 L/min,
and FiO2 100%. We tried to use negative liquid equilibrium to improve the left heart failure at the early
stage of VVA ECMO. The negative fluid balance at the first and second day was, respectively, 272 and
345 mL. As a result, the CVP of the young man decreased to 28 mmHg and his circulation tended to
deteriorate. In order to maintain his circulation, the dose of noradrenaline had to adjust from 0.7 to 1.4
ug/kg/min. Then we tried to change the liquid management strategy. The cumulative positive balance
was 10000 mL in the following 7 d. His CVP gradually increased to 35 mmHg and the dose of
noradrenaline was gradually tapered until stopped on April 20, 2018. The oxygenator and circulation
line of ECMO were replaced as the equipment had achieved its design life on April 23, 2018. As
ventilator weaning was difficult in a short period for the patient, tracheotomy was operated on April 27,
2018. As circulation and respiratory function gradually improved, VVA ECMO equipment was removed
on May 1, 2018.
OUTCOME AND FOLLOW-UP
The patient was successfully withdrawn from artificial ventilation on May 28, 2018 and then discharged
from hospital on May 30, 2018. We followed him at his home on October 25, 2021, and he can take care
of himself in daily life and engage in light manual labor.
DISCUSSION
As research reported in 2005, double outlet right ventricle (DORV) occurs in 0.09 cases per 1000 live
births. As a rare congenital heart disease, the Tausing-Bing anomaly is the third most common type of
DORV[5]. So far, the Fontan operation was the only treatment option to change the anatomy of the heart
and help improve patients’ hemodynamics[1]. After successful operation, patients typically recover the
ability to engage in general physical activity. H1N1 influenza has a higher case fatality among younger
patients and the potential for fulminant ARDS[6]. The mortality of patients diagnosed with ARDS
ranges from 17.3% to 41.4% among critically ill patients with H1N1 infection[2,3]. As a better ventilatory
strategy, as well as an alternative mode of respiratory support, ECMO provides gas exchange via an
extracorporeal circuit, and is increasingly being used to improve respiratory and circulatory function
[7]. ECMO is usually used to help patients get through postoperative difficulties such as heart failure
and hemodynamically unstable and refractory arrhythmias. As the morbidity and mortality associated
with ECMO are relatively high, the survival of children with heart disease that need ECMO support is
only 33%-60%[8].
By analyzing the medical history and imaging manifestations, we concluded the direction of blood
flow in this case (Figure 2C): Right atrium, pulmonary artery, pulmonary vein, left atrium, left ventricle,
right ventricle, aorta, and right atrium. By analyzing data from the Extracorporeal Life Support
Organization, we found that only 35% of cardiac failure patients subjected to Fontan operation survived
to hospital discharge[4]. By analyzing the medical history and imaging results of the patient, there were
mainly three factors causing the severe respiratory failure. First, due to the special physiological
structure after the operation of Fontan, a single ventricle was more vulnerable to suffering severe left
heart failure compared with a normal heart. Furthermore, pulmonary edema caused by the acute left
ventricular failure was one of the reasons for respiratory failure. Second, the pulmonary infection
caused by H1N1 influenza affected his respiratory function. Thus, severe ARDS might be the second
cause of severe respiratory failure. Third, pulmonary arterial hypertension might aggravate systemic
circulation congestion and lead to left ventricular preload insufficiency.
Guo HB et al. ECMO in a patient after Fontan operation
WJCC https://www.wjgnet.com 10619 October 16, 2022 Volume 10 Issue 29
The patient’s circulation after the Fontan surgery was different than that of a normal patient.
Therefore, supporting Fontan patients on ECMO carries high morbidity and mortality[4]. After the
Fontan operation, pulmonary and systemic circulation are mainly sustained by the single ventricle. A
study found that patients for whom the Fontan operation was not successful usually suffered anatomic
obstruction to flow, pulmonary vascular remodeling, atrioventricular valve dysfunction, univentricular
diastolic dysfunction and chronic underfilling, and/or univentricular systolic dysfunction[9]. There are
three stages of failure in a Fontan patient, each of which is associated with certain underlying etiologies
[10]. Early Fontan failure is often marked by anatomic obstruction. Most patients usually have an early
acute onset of failure, prior to end organ injury[11]. Patients with middle and late phase Fontan failure
usually exhibit signs of end organ damage. Late phase failure patients present protein losing
enteropathy, plastic bronchitis, cirrhosis, or renal failure in the process of medical treatment[12]. In this
case, after the Fontan operation, the right atrium of the patient was directly linked with the pulmonary
artery. The CVP of the patient at admission to the ICU was 40 mmHg, therefore he was diagnosed with
pulmonary hypertension. As his circulation depended on the single ventricle, severe sepsis accelerated
the process of heart failure. At the beginning of treatment, it was hard to improve the systemic and
pulmonary circulation congestion.
Relevant research noted that about 30% of Fontan patients suffered from heart failure in 20 years[13,
14]. Patients with neurologic complications, surgical bleeding, and renal failure were inclined to have a
higher mortality during the course of ECMO, indicating that ECMO complications may limit survival
outcomes for these patients[4]. The patient initially received VV ECMO treatment for severe respiratory
failure on April 6, 2018. Even though the man’s respiratory function significantly improved with the
help of VV ECMO, shock persisted and did not effectively relieve. By analyzing the pathophysiological
characteristics of his heart anatomical structure, we concluded that severe left heart failure might
explain the refractory shock. Then, in response to severe heart failure and cardiogenic shock, the VV
ECMO was converted to VVA ECMO. The shock was significantly improved with the help of VVA
ECMO. Vasoactive drugs were disused in 1 d after the mode of the machine was switched.
We tried to use negative liquid equilibrium to improve the left heart failure at the early stages of VVA
ECMO, but failed. The negative liquid equilibrium was smoothly conducted 3 d after the mode of
ECMO was changed. As pulmonary pressure of the case was high, the right ventricular ejection
depended on pressure differences and needed a higher volume. With the improvement of cardiac
function and oxygen, heart and respiratory failures were effectively improved. Meanwhile, pulmonary
arterial hypertension declined to some extent, making negative liquid equilibrium a feasible option. In
the case, the proper CVP might be 35 mmHg. We had to search a suitable liquid state to balance both the
respiratory and circulatory systems. Therefore, an individualized liquid management strategy was
necessary.
With the help of VVA ECMO, heart failure and shock were gradually improved. After about 20 d of
circulation support, the patient successfully had the VVA ECMO equipment removed. Due to the
special cardiac structure and circulatory characteristics, it might be better for him to choose an active
circulation support earlier. Other modes such as VAV ECMO might be another choice, especially for
those who have a risk of different hypoxia, in which cardiac recovery precedes lung recovery[15]. For
this case, VAV ECMO would provide the right atrium with oxygen-rich blood and improve coronary
oxygen supply, which might be better for heart recovery.
Different types of antibiotics were used throughout the course of the disease. The structural
abnormality of the heart and congestive heart failure increased pulmonary edema and aggravated
pulmonary infection. Meanwhile, longer duration of ECMO increased the risk of bloodstream infection.
Although the outcome in our research was favorable, it is important to note that the case took a longer
ECMO course to achieve lung recovery[16]. Most previous studies had demonstrated the use of ECMO
in patients with the Fontan operation for cardiac support, but this case illustrated its value as a bridge to
lung recovery in acute respiratory failure due to pH1N1 infection.
CONCLUSION
The circulation after the modified Fontan operation is different from that of patients who does not
undergo the operation. There are certainly many differences between them when they receive the
treatment of ECMO. Due to the special cardiac structure and circulatory characteristics, it might be
better for them to choose an active circulation support earlier.
FOOTNOTES
Author contributions: Liu JY and Hou XT designed the research study and provided research ideas; Guo Hb and Tan
JB were major contributors in writing the manuscript; Cui YC, Xiong HF, Li CS, Liu YF, Sun Y, Pu L, Xiang P, Zhang
M, Hao JJ, and Yin NN read the literature and collected the patient’s medical records; all authors read and approved
the final manuscript.
Guo HB et al. ECMO in a patient after Fontan operation
WJCC https://www.wjgnet.com 10620 October 16, 2022 Volume 10 Issue 29
Supported by the Capital Foundation of Medical Development, No. 2018-1-2171; and the Seedling Plan from the
Beijing Ditan Hospital, Capital Medical University, No. DTYM201802.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report
and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was
prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by
external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-
NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license
their derivative works on different terms, provided the original work is properly cited and the use is non-
commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Country/Territory of origin: China
ORCID number: He-Bing Guo 0000-0002-7353-7795; Jian-Bo Tan 0000-0002-0694-2555; Yong-Chao Cui 0000-0001-8968-
8961; Hao-Feng Xiong 0000-0002-9282-8694; Chuan-Sheng Li 0000-0003-3538-7295; Yu-Feng Liu 0000-0003-1710-0270;
Yao Sun 0000-0001-8169-9404; Lin Pu 0000-0002-5659-2848; Pan Xiang 0000-0001-8302-9770; Ming Zhang 0000-0003-3092-
918X; Jing-Jing Hao 0000-0001-9347-1351; Ning-Ning Yin 0000-0003-3359-2447; Xiao-Tong Hou 0000-0002-7047-0492;
Jing-Yuan Liu 0000-0002-0592-9789.
S-Editor: Xing YX
L-Editor: Wang TQ
P-Editor: Xing YX
REFERENCES
Peer SM, Deatrick KB, Johnson TJ, Haft JW, Pagani FD, Ohye RG, Bove EL, Rojas-Peña A, Si MS. Mechanical
Circulatory Support for the Failing Fontan: Conversion to Assisted Single Ventricle Circulation-Preliminary Observations.
World J Pediatr Congenit Heart Surg 2018; 9: 31-37 [PMID: 29310555 DOI: 10.1177/2150135117733968]
1
Töpfer L, Menk M, Weber-Carstens S, Spies C, Wernecke KD, Uhrig A, Lojewski C, Jörres A, Deja M. Influenza A
(H1N1) vs non-H1N1 ARDS: analysis of clinical course. J Crit Care 2014; 29: 340-346 [PMID: 24508203 DOI:
10.1016/j.jcrc.2013.12.013]
2
Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F,
Turgeon AF, Lapinsky S, Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J,
Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, Meade M, Hall
R, Fowler RA; Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza
A(H1N1) infection in Canada. JAMA 2009; 302: 1872-1879 [PMID: 19822627 DOI: 10.1001/jama.2009.1496]
3
Rood KL, Teele SA, Barrett CS, Salvin JW, Rycus PT, Fynn-Thompson F, Laussen PC, Thiagarajan RR. Extracorporeal
membrane oxygenation support after the Fontan operation. J Thorac Cardiovasc Surg 2011; 142: 504-510 [PMID:
21353253 DOI: 10.1016/j.jtcvs.2010.11.050]
4
Walters HL 3rd, Mavroudis C, Tchervenkov CI, Jacobs JP, Lacour-Gayet F, Jacobs ML. Congenital Heart Surgery
Nomenclature and Database Project: double outlet right ventricle. Ann Thorac Surg 2000; 69: S249-S263 [PMID:
10798433 DOI: 10.1016/s0003-4975(99)01247-3]
5
Jaber S, Conseil M, Coisel Y, Jung B, Chanques G. [ARDS and influenza A (H1N1): patients' characteristics and
management in intensive care unit. A literature review]. Ann Fr Anesth Reanim 2010; 29: 117-125 [PMID: 20116970 DOI:
10.1016/j.annfar.2009.12.026]
6
Brodie D. The Evolution of Extracorporeal Membrane Oxygenation for Adult Respiratory Failure. Ann Am Thorac Soc
2018; 15: S57-S60 [PMID: 29461889 DOI: 10.1513/AnnalsATS.201705-386KV]
7
Cooper DS, Jacobs JP, Moore L, Stock A, Gaynor JW, Chancy T, Parpard M, Griffin DA, Owens T, Checchia PA,
Thiagarajan RR, Spray TL, Ravishankar C. Cardiac extracorporeal life support: state of the art in 2007. Cardiol Young
2007; 17 Suppl 2: 104-115 [PMID: 18039404 DOI: 10.1017/S1047951107001217]
8
Anderson PA, Sleeper LA, Mahony L, Colan SD, Atz AM, Breitbart RE, Gersony WM, Gallagher D, Geva T, Margossian
R, McCrindle BW, Paridon S, Schwartz M, Stylianou M, Williams RV, Clark BJ 3rd; Pediatric Heart Network
Investigators. Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. J Am Coll
Cardiol 2008; 52: 85-98 [PMID: 18598886 DOI: 10.1016/j.jacc.2008.01.074]
9
Bock MJ, Pahl E, Rusconi PG, Boyle GJ, Parent JJ, Twist CJ, Kirklin JK, Pruitt E, Bernstein D. Cancer recurrence and
mortality after pediatric heart transplantation for anthracycline cardiomyopathy: A report from the Pediatric Heart
Transplant Study (PHTS) group. Pediatr Transplant 2017; 21 [PMID: 28378408 DOI: 10.1111/petr.12923]
10
Deal BJ, Costello JM, Webster G, Tsao S, Backer CL, Mavroudis C. Intermediate-Term Outcome of 140 Consecutive
Fontan Conversions With Arrhythmia Operations. Ann Thorac Surg 2016; 101: 717-724 [PMID: 26602004 DOI:
10.1016/j.athoracsur.2015.09.017]
11
Guo HB et al. ECMO in a patient after Fontan operation
WJCC https://www.wjgnet.com 10621 October 16, 2022 Volume 10 Issue 29
Woods RK, Ghanayem NS, Mitchell ME, Kindel S, Niebler RA. Mechanical Circulatory Support of the Fontan Patient.
Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2017; 20: 20-27 [PMID: 28007060 DOI:
10.1053/j.pcsu.2016.09.009]
12
d'Udekem Y, Iyengar AJ, Galati JC, Forsdick V, Weintraub RG, Wheaton GR, Bullock A, Justo RN, Grigg LE, Sholler
GF, Hope S, Radford DJ, Gentles TL, Celermajer DS, Winlaw DS. Redefining expectations of long-term survival after the
Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation
2014; 130: S32-S38 [PMID: 25200053 DOI: 10.1161/CIRCULATIONAHA.113.007764]
13
Oldenburger NJ, Mank A, Etnel J, Takkenberg JJ, Helbing WA. Drug therapy in the prevention of failure of the Fontan
circulation: a systematic review. Cardiol Young 2016; 26: 842-850 [PMID: 26947621 DOI: 10.1017/S1047951115002747]
14
Vogel DJ, Murray J, Czapran AZ, Camporota L, Ioannou N, Meadows CIS, Sherren PB, Daly K, Gooby N, Barrett N.
Veno-arterio-venous ECMO for septic cardiomyopathy: a single-centre experience. Perfusion 2018; 33: 57-64 [PMID:
29788842 DOI: 10.1177/0267659118766833]
15
Gandhi NN, Hartman ME, Williford WL, Peters MA, Cheifetz IM, Turner DA. Successful use of extracorporeal membrane
oxygenation for pH1N1-induced refractory hypoxemia in a child with hypoplastic left heart syndrome. Pediatr Crit Care
Med 2011; 12: e398-e401 [PMID: 21116209 DOI: 10.1097/PCC.0b013e3181fe3189]
16
Published by Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com
© 2022 Baishideng Publishing Group Inc. All rights reserved.
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Background: Mechanical circulatory support (MCS) of a failing Fontan circulation remains challenging. We hypothesized that MCS can be provided by converting the Fontan circulation into a mechanically assisted single ventricle parallel circulation (MASVC). Methods: A porcine model of functionally univentricular circulation was created under cardiopulmonary bypass (CPB) by performing an atrial septectomy, tricuspid valvectomy, and interrupting antegrade pulmonary blood flow. A centrifugal flow pump was placed with inflow from the common atrium. Eight millimeter Dacron grafts anastomosed to the ascending aorta and main pulmonary artery supplied systemic (Qs) and pulmonary (Qp) blood flow. Ultrasonic flow probes were used to measure Qs and Qp after weaning from CPB. The Qp/Qs ratio was regulated using an adjustable clamp. Hemodynamic and laboratory data were recorded. Results: All four animals were successfully weaned from CPB onto the MASVC for a duration of two hours. Mechanically assisted single ventricle parallel circulation achieved satisfactory hemodynamics. As anticipated, the arterial oxygen saturation and partial pressure of oxygen in arterial blood were lower in the MASVC compared to baseline biventricular circulation. At the conclusion of the study, there was a trend towards a decrease in the mixed venous saturation with increasing oxygen extraction compared to the baseline. Serum lactate levels increased after weaning from CPB and did not return to baseline after two hours of support. Conclusion: Mechanically assisted single ventricle parallel circulation can be established in a single ventricle animal model. This strategy could potentially provide MCS of a single ventricle circulation. Studies with longer duration of support are required to assess adequacy of support and long-term sustainability.
Article
Full-text available
Background: The Fontan circulation is the optimal treatment for patients with univentricular hearts. These patients are at high risk of circulatory failure. There is no consensus on the optimal drug treatment for the prevention of failure of the Fontan circulation. The aim of this systematic review was to provide an overview of evidence for drug therapy used in the prevention of Fontan circulatory failure. Methods: We searched the Embase database for articles that reported drug therapy in Fontan patients. Studies published between 1997 and 2014 were included if efficacy or safety of medication was assessed, drug therapy aimed to prevent or treat failure of the Fontan circulation, and if the full text was available. Case reports were excluded. Results: A total of nine studies were included with a total of 267 Fontan patients; four studies evaluated the medication sildenafil, one iloprost, three bosentan, and one enalapril. Among all, two sildenafil studies reported improvement in exercise capacity, one in exercise haemodynamics, and one in ventricular performance. In the largest study of bosentan, an increase in exercise capacity was found. Enalapril did not result in improvements. Conclusion: The studies analysed in this review suggest that bosentan, sildenafil, and iloprost may improve exercise capacity at the short term. Given the limitations of the studies, more, larger, placebo-controlled studies with longer follow-up periods are needed to better understand which drug therapies are effective in the prevention of failure of the Fontan circulation.
Article
Introduction: The role of extracorporeal support for patients with septic shock remains unclear. Methods: We conducted a retrospective analysis of our single-centre experience with veno-arterio-venous extracorporeal membrane oxygenation (VAV ECMO) in adult patients with severe respiratory failure and septic cardiomyopathy. Clinical data was extracted from electronic medical records including a dedicated ECMO referral and follow-up database. Results: Twelve patients were commenced on VAV ECMO for septic cardiomyopathy for a median of four days (IQR 3.0 to 5.3) between 01/2014 and 12/2017. Five patients (41.7%) had a cardiac arrest prior to initiation of ECMO support. At baseline, median left ventricular ejection fraction was 16.25% (IQR 13.13 to 17.5) and median PaO2/FiO2 ratio was 9 kPa (IQR 6.5 to 12.0) [67.50 mmHg (IQR 48.75 to 90.00)]. The survival rate to hospital discharge for VAV ECMO was 75% in this cohort. None of the surviving patients died within the follow-up period (median six month). Conclusion: VAV ECMO is a feasible rescue strategy for a small proportion of patients with combined respiratory and cardiac failure secondary to septic shock with septic cardiomyopathy. We provide a detailed report of our experience with this technique. Further research is required comparing the different extracorporeal strategies directly to conventional resuscitation and against each other.
Article
The use of extracorporeal membrane oxygenation to support patients with cardiac and respiratory failure has increased substantially in the last decade. Although the evidence base for its use in adults with respiratory failure is growing, many questions remain to be answered. Ongoing research is aimed at clarifying the role of extracorporeal membrane oxygenation, as well as extracorporeal carbon dioxide removal, in various forms of hypoxemic and hypercapnic respiratory failure, and at defining the optimal techniques for its use. This, of course, is a moving target, as advances in the technology of extracorporeal membrane oxygenation, and the potential development of a true artificial lung, continue at a brisk pace.
Article
We aimed to determine whether malignancy after pediatric HTx for ACM affects overall post-HTx survival. Patients <18y listed for HTx for ACM in the PHTS database between 1993 and 2014 were compared to those with DCM. A 2:1 matched DCM cohort was also compared. Wait-list and post-HTx survival, along with freedom from common HTx complications, were compared. Eighty subjects were listed due to ACM, whereas 1985 were listed for DCM. Although wait-list survival was higher in the ACM group, post-HTx survival was lower for the ACM cohort. Neither difference persisted in the matched cohort analysis. Primary cause of death in the ACM group was infection, which was higher than the DCM group. Malignancy rates were not different. All ACM malignancies were due to PTLD without primary cancer recurrence or SMN. Long-term graft survival after pediatric HTx for ACM is no different than for matched DCM peers, nor is there an increased risk of any malignancy. However, risk of infection and death from infection after HTx are higher in the ACM group. Further studies are needed to assess the effects of prior chemotherapy on susceptibility to infection in this group.
Article
Because of the inadequacies inherent to a circulation supported by a single ventricle, many Fontan patients will experience failure of their circulation. To date, there is no medical regimen that reliably and consistently restores circulatory function in these patients. Because of the shortage of donor organs and the fact that many of these patients present with features that either preclude or render heart transplantation a high risk, there is an intense need to better understand how mechanical circulatory support (MCS) may benefit these patients. In this report, we share our experience of successful MCS and transplantation of three patients. Our experience and that of others is very encouraging, but also preliminary. In general, a systemic ventricular assist device, with or without a Fontan fenestration, is a reasonable consideration for a patient presenting with predominantly systolic dysfunction. A pulmonary/systemic venous assist device may be sufficient for the patient with preserved systolic function and failure of the systemic venous/lymphatic system; however, this remains speculative. The more comprehensive approach of a total artificial heart or bilateral support is attractive in theory, but beset by the need for a more complex operation. In all scenarios, early referral, before organ failure, is paramount to successful MCS.
Article
Background: Atrial arrhythmias and progressive circulatory failure frequently develop in patients with a Fontan circulation. Improvement of flow dynamics and revision of the arrhythmia substrate may improve outcomes in selected patients. We sought to determine intermediate-term outcomes after Fontan conversion with arrhythmia operations and identify characteristics associated with decreased transplant-free survival. Methods: The first 140 Fontan conversions with arrhythmia operations at a single institution were analyzed for predictors of cardiac death or transplant and incidence of arrhythmia recurrence. Results: The median age at the Fontan conversion operation was 23.2 years (range, 2.6 to 47.3 years). Preoperative arrhythmias were present in 136 patients: right atrial tachycardia in 48 patients, left atrial tachycardia in 21, and atrial fibrillation in 67. Freedom from cardiac death or transplant was 90% at 5 years, 84% at 10 years, and 66% at 15 years. The median age at the last follow-up among survivors was 32 years (range, 15 to 61 years). By multivariable analysis, risk factors for cardiac death or heart transplantation were a right or indeterminate ventricular morphology, cardiopulmonary bypass time exceeding 240 minutes, ascites, protein-losing enteropathy, or a biatrial arrhythmia operation at the time of conversion. Freedom from recurrence of atrial tachycardia was 77% at 10 years. Among 67 patients with atrial fibrillation undergoing biatrial arrhythmia operations, none had recurrent atrial fibrillation. Conclusions: Freedom from cardiac death or transplant for patients undergoing Fontan conversion with an arrhythmia operation is 84% at 10 years. The effects of atrial arrhythmia operations are durable in most patients. These outcomes may serve as useful benchmarks for alternative management strategies.
Article
Background: The life expectancy of patients undergoing a Fontan procedure is unknown. Methods and results: Follow-up of all 1006 survivors of the 1089 patients who underwent a Fontan procedure in Australia and New Zealand was obtained from a binational population-based registry including all pediatric and adult cardiac centers. There were 203 atriopulmonary connections (AP; 1975-1995), 271 lateral tunnels (1988-2006), and 532 extracardiac conduits (1997-2010). The proportion with hypoplastic left heart syndrome increased from 1/173 (1%) before 1990 to 80/500 (16%) after 2000. Survival at 10 years was 89% (84%-93%) for AP and 97% (95% confidence interval [CI], 94%-99%) for lateral tunnels and extracardiac conduits. The longest survival estimate was 76% (95% CI, 67%-82%) at 25 years for AP. AP independently predicted worse survival compared with extracardiac conduits (hazard ratio, 6.2; P<0.001; 95% CI, 2.4-16.0). Freedom from failure (death, transplantation, takedown, conversion to extracardiac conduits, New York Heart Association III/IV, or protein-losing enteropathy/plastic bronchitis) 20 years after Fontan was 70% (95% CI, 63%-76%). Hypoplastic left heart syndrome was the primary predictor of Fontan failure (hazard ratio, 3.8; P<0.001; 95% CI, 2.0-7.1). Ten-year freedom from failure was 79% (95% CI, 61%-89%) for hypoplastic left heart syndrome versus 92% (95% CI, 87%-95%) for other morphologies. Conclusions: The long-term survival of the Australia and New Zealand Fontan population is excellent. Patients with an AP Fontan experience survival of 76% at 25 years. Technical modifications have further improved survival. Patients with hypoplastic left heart syndrome are at higher risk of failure. Large, comprehensive registries such as this will further improve our understanding of late outcomes after the Fontan procedure.
Article
The purpose of the study is to compare H1N1-induced acute respiratory distress syndrome (ARDS) with ARDS due to other causes of severe community-acquired pneumonia focusing on pulmonary function. This is a retrospective data analysis of adult ARDS patients between January 2009 and December 2010 in an ARDS referral center. Patient characteristics, severity of illness scores, modalities, and duration of extracorporeal lung support were evaluated as well as intensive care unit stay and survival. Parameters of mechanical ventilation and pulmonary function were analyzed on day of admission and over the consecutive 10 days using a nonparametric analysis of longitudinal data in a 2-factorial design. In a logistic regression analysis, risk factors for extracorporeal lung support were investigated. Twenty-one patients with H1N1-ARDS and 41 with non-H1N1-ARDS were identified. Gas exchange was more severely impaired in patients with H1N1-ARDS over course of time. Extracorporeal membrane oxygenation was more frequently needed in H1N1-ARDS. Despite significantly prolonged weaning off extracorporeal lung support and intensive care unit stay in H1N1 patients, the proportion of survivors did not differ significantly. Only Sepsis-Related Organ Failure Assessment score could be identified as an independent predictor of extracorporeal lung support. Clinical course of H1N1-ARDS is substantially different from non-H1N1-ARDS. Affected patients may require extensive therapy including extracorporeal lung support in ARDS referral centers.
Article
Extracorporeal membrane oxygenation has been used to support children with cardiac failure after the Fontan operation. Mortality is high, and causes of mortality remain unclear. We evaluated the in-hospital mortality and factors associated with mortality in these patients. Extracorporeal Life Support Organization registry data on patients requiring extracorporeal membrane oxygenation after the Fontan operation from 1987 to 2009 were retrospectively analyzed. Demographics and extracorporeal membrane oxygenation data were compared for survivors and nonsurvivors. A multivariable logistic regression model was used to identify factors associated with mortality. Of 230 patients, 81 (35%) survived to hospital discharge. Cardiopulmonary resuscitation was more frequent (34% vs 17%, P = .04), and median fraction of inspired oxygen concentration was higher (1 [confidence interval, 0.9-1.0] vs 0.9 [confidence interval, 0.8-1.0], P = .03) before extracorporeal membrane oxygenation in nonsurvivors compared with survivors. Extracorporeal membrane oxygenation duration and incidence of complications, including surgical bleeding, neurologic injury, renal failure, inotrope use on extracorporeal membrane oxygenation, and bloodstream infection, were higher in nonsurvivors compared with survivors (P < .05 for all). In a multivariable model, neurologic injury (odds ratio, 5.18; 95% confidence interval, 1.97-13.61), surgical bleeding (odds ratio, 2.36; 95% confidence interval, 1.22-4.56), and renal failure (odds ratio, 2.81; 95% confidence interval, 1.41-5.59) increased mortality. Extracorporeal membrane oxygenation duration of more than 65 hours to 119 hours (odds ratio, 0.33; 95% confidence interval, 0.14-0.76) was associated with decreased mortality. Cardiac failure requiring extracorporeal membrane oxygenation after the Fontan operation is associated with high mortality. Complications during extracorporeal membrane oxygenation support increase mortality odds. Prompt correction of surgical bleeding when possible may improve survival.